Lupin Limited has announced the allotment of 169,140 equity shares under its Employee Stock Option Plan (ESOP), marking another step in the pharmaceutical company's employee incentive program. The allotment was approved by the company's Operations and Finance Committee during its meeting held on January 27, 2026.

Share Allotment Details

The company allotted 169,140 fully paid-up equity shares of ₹ 2 each to employees of the company and its subsidiaries. These shares were issued following the exercise of vested options granted under Lupin's stock option plans.

Impact on Share Capital

Following the ESOP allotment, Lupin's capital structure has been updated to reflect the increased shareholding base. The allotment has resulted in an expansion of the company's equity base.

Regulatory Compliance

The allotment was disclosed to stock exchanges in compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company informed both the National Stock Exchange of India Limited and BSE Limited about the share allotment.

The disclosure was signed by Amit Kumar Gupta, Company Secretary and Compliance Officer, ensuring proper regulatory adherence. This ESOP allotment represents Lupin's continued commitment to employee participation in the company's growth through equity-based compensation schemes.

Lupin Limited has achieved a significant milestone in environmental sustainability by receiving the highest 'A' leadership rating from Climate Disclosure Project (CDP) for both Climate Change and Water Security categories. This recognition positions the global pharmaceutical company among distinguished leaders who champion sustainability and transparency at the highest level.

Exceptional Performance in ESG Ratings

The double 'A' rating demonstrates Lupin's exceptional accomplishments in climate action and water management. This achievement represents substantial enhancement compared to the company's previous performance, showcasing consistent year-over-year progress in environmental stewardship.

Comprehensive Sustainability Commitment

Lupin's outstanding ratings reflect the company's steadfast commitment to sustainability through proactive initiatives aimed at mitigating climate risks, reducing carbon emissions, and ensuring responsible water management throughout its operations. The CDP's rigorous scoring framework evaluates organizations on governance, strategy, risk management, and performance metrics related to climate and water, driving accountability and action across global markets.

Ramesh Swaminathan, Executive Director, Global CFO and Head – API Plus SBU at Lupin, emphasized the company's dedication to environmental responsibility. He highlighted how CDP's strict framework has helped shape and accelerate the company's climate initiatives, fostering ongoing progress in establishing new sustainability standards and generating lasting value for communities and the planet.

Additional ESG Recognition

Beyond the CDP achievement, Lupin has demonstrated excellence across multiple ESG evaluation platforms. The company achieved an impressive S&P Global ESG score of 91.00 in 2025, representing a best-in-class global achievement that positions Lupin among an elite group of companies worldwide surpassing the 90-point threshold.

Global Pharmaceutical Leadership

As a global pharmaceutical leader headquartered in Mumbai, India, Lupin distributes products across over 100 markets worldwide. The company specializes in pharmaceutical products including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Lupin maintains a strong position in India and the United States across multiple therapy areas, supported by 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 24,000 professionals.

Source: